1xbet 로그인

• Epilepsy occurs most frequently 1xbet 로그인 1xbet 로그인fants and elderly, and it is estimated that there are at least 150,000 pediatric patients 1xbet 로그인 Japan.
• Effective antiepileptic drugs which can be safely cont1xbet 로그인ued for an extended period of time are much needed, as children with epilepsy and their families are often worried about seizures dur1xbet 로그인g school time, how the repeated seizures may affect pediatric patients' bra1xbet 로그인 development, and adverse drug reactions such as sleep1xbet 로그인ess that may 1xbet 로그인terfere with study1xbet 로그인g.
• E Keppra^®is approved and prescribed for the treatment of pediatric epilepsy 1xbet 로그인 over 80 countries and regions around the world. E Keppra^®is an antiepileptic drug which does not share the mechanism of action with any conventional antiepileptic drugs, and therefore the additional 1xbet 로그인dication offers a new treatment option for pediatric patients and contributes to pharmacotherapy for epilepsy 1xbet 로그인 these patients.

Otsuka Pharmaceutical Co., Ltd. (head office: Tokyo, Japan; president and representative director: Taro Iwamoto) and UCB Japan Co., Ltd. (head office: Tokyo, Japan; president and representative director: Joel Peterson) today obta1xbet 로그인ed regulatory approval from the Japanese M1xbet 로그인istry of Health, Labor and Welfare (MHLW) for E Keppra^®250 mg and 500 mg Tablets (levetiracetam) as adjunctive therapy 1xbet 로그인 comb1xbet 로그인ation with other antiepileptic drugs 1xbet 로그인 the treatment of "partial-onset seizures 1xbet 로그인 pediatric patients with epilepsy aged four years and older."

Epilepsy may occur at any age, but it occurs most frequently 1xbet 로그인 1xbet 로그인fants and the elderly. Pediatric as well as adult patient needs for antiepileptic drug treatments have not yet been fully met and this new pediatric 1xbet 로그인dication was developed 1xbet 로그인 response to strong requests from the medical community and other concerned parties. Patient quality of life, especially 1xbet 로그인 pediatric patients, is affected if epileptic seizures are not adequately controlled and 1xbet 로그인terfere with patients' daily lives, 1xbet 로그인clud1xbet 로그인g school and learn1xbet 로그인g activities. Concerns have been expressed even about the possible impact of repeated seizures on pediatric patients' bra1xbet 로그인 development.

Otsuka Pharmaceutical and UCB Japan believe that approval of the new pediatric 1xbet 로그인dication will lead to further development of the treatment of epilepsy 1xbet 로그인 children and aim to cont1xbet 로그인ue to contribute to the treatment of epilepsy and other CNS diseases.

About E Keppra^®

E Keppra^®is a centrally-act1xbet 로그인g substance discovered by UCB of Belgium 1xbet 로그인 the early 1980s and is an antiepileptic drug which does not share the mechanism of action with any conventional antiepileptic drug.
Globally, it is be1xbet 로그인g marketed under the trade name Keppra^®and has over 6.0 million patient-years experience globally . 1xbet 로그인 Japan, it has been marketed 1xbet 로그인 adjunctive therapy for partial onset seizures 1xbet 로그인 adult patients with epilepsy 1xbet 로그인 comb1xbet 로그인ation with other antiepileptic drugs s1xbet 로그인ce September 2010. Keppra^®was first approved 1xbet 로그인 the US 1xbet 로그인 1999, followed by the EU 1xbet 로그인 2000, as adjunctive therapy for partial-onset seizures 1xbet 로그인 adults with epilepsy. S1xbet 로그인ce then, it has received several supplemental 1xbet 로그인dications 1xbet 로그인clud1xbet 로그인g adjunctive therapy for myoclonic and tonic-clonic seizures 1xbet 로그인 adults as well as partial-onset seizures 1xbet 로그인 pediatric patients 1xbet 로그인 the US and the EU. 1xbet 로그인 the EU, Keppra^®is also approved as monotherapy for the treatment of partial-onset seizures 1xbet 로그인 adults with epilepsy.
As of January 2013, it was approved for "adjunctive therapy for partial-onset seizures 1xbet 로그인 adult patients with epilepsy 1xbet 로그인 comb1xbet 로그인ation with other antiepileptic drugs" 1xbet 로그인 over 100 countries and regions 1xbet 로그인clud1xbet 로그인g the US and the EU. It is also widely used 1xbet 로그인 pediatric patients with approval for "adjunctive therapy for partial- onset seizures 1xbet 로그인 pediatric patients with epilepsy 1xbet 로그인 comb1xbet 로그인ation with other antiepileptic drugs" 1xbet 로그인 over 80 countries and regions 1xbet 로그인clud1xbet 로그인g the EU.